|
【结 构 式】 
|
【药物名称】Mitozantrone hydrochloride, Mitoxantrone hydrochloride, DAD, NSC-301739, CL-232315, Onkotrone, Novantrone, Novantron 【化学名称】1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-9,10-anthracenedione dihydrochloride 【CA登记号】70476-82-3, 65271-80-9 (free base) 【 分 子 式 】C22H30Cl2N4O6 【 分 子 量 】517.4136 |
【开发单位】Amgen (Originator), Wyeth Pharmaceuticals (Originator), Baxter Oncology (Not Determined), OSI (Marketer), Serono (Licensee), Takeda (Licensee) 【药理作用】Breast Cancer Therapy, Immunologic Neuromuscular Disorders, Treatment of, Leukemia Therapy, Liver Cancer Therapy, Lymphoma Therapy, Multiple Sclerosis, Agents for, Myeloid Leukemia Therapy, NEUROLOGIC DRUGS, Non-Hodgkin's Lymphoma Therapy, Oncolytic Drugs, Prostate Cancer Therapy, DNA Topoisomerase II Inhibitors |
合成路线1
By reaction of 5,8-dihydroxyleucoquinizarin (1,4,5,8-tetrahydroxy-9,10-anthraquinone) (I) with 2-(aminoethylamino)ethanol (II) in dioxane at 60 C.
| 【1】 Zee-Cheng, R.K.Y.; Cheng, C.C.; Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones. J Med Chem 1978, 21, 3, 291-294. |
| 【2】 Blancafort, P.; Sweetman, A.J.; Castaner, J.; Serradell, M.N.; CL-232315. Drugs Fut 1980, 5, 5, 234. |